The assay performance evaluation in future studies will require employing a more representative and comprehensive cohort of patients, including HER2 3 + , triple-negative cases, and especially HER2-low tumors, as recently emerging new subtype of breast cancer. Here, ERBB2 is linked to breast carcinoma.